The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.